Tarsus Pharmaceuticals (TARS) Q2 FY26 earnings call

Tarsus Pharmaceuticals reported a strong second quarter, driven by record sales of XDEMVY, which continues to exceed expectations and is on track for over $2 billion in potential annual peak sales. The company also announced the strategic acquisition of Alkeus Pharmaceuticals, adding gildeuretinol (ALK-001), a late-stage investigational therapy for Stargardt disease, to its retina pipeline. This move broadens Tarsus's presence in the retina specialty, leveraging XDEMVY's commercial success to fund future growth and build a leading eye care company with multiple potential blockbuster medicines.